Abstract
Objective:
Our study aimed to investigate the expression level and clinical significance of serum and exhaled breath condensate miR-186 and IL-1β in non-small cell lung cancer patients.
Methods:
The serum and exhaled breath condensate specimens of 62 non-small cell lung cancer patients and 60 healthy controls were collected to detect miR-186 expression levels by real-time fluorescent quantitative PCR. Enzyme linked immunosorbent assay was applied to examine IL-1β concentration. Statistical analyses were used to evaluate the correlation between miR-186 and IL-1β in serum and clinicopathological features, traditional serum tumor markers, and inflammatory markers. The diagnostic efficacy of miR-186 and IL-1β for non-small cell lung cancer was evaluated by receiver operating characteristic curve analysis. The correlation between miR-186 and IL-1β was determined.
Results:
① The relative expression level of miR-186 was greatly reduced in the serum and EBC of patients with non-small cell lung cancer, and the miR-186 expression level was reduced in different TNM stages of non-small cell lung cancer, from the early to later stages. ② The IL-1β concentration in serum and exhaled breath condensate of patients with non-small cell lung cancer was increased. ③ Serum miR-186 and IL-1β levels were closely related to lymph node metastasis, and the low expression of serum miR-186 and the high concentration of IL-1β were associated with higher serum carcinoembryonic antigen, C-reactive protein, and erythrocyte sedimentation rate levels. ④ ROC curve analysis showed that exhaled breath condensate miR-186 had higher area under the curve than serum miR-186, and the combined detection showed higher diagnostic efficacy than the separate detection. In addition, the combined detection of IL-1β and miR-186 has a larger AUC than the separate detection of both. ⑤ The correlation between serum miR-186 and IL-1β was negative.
Conclusion:
miR-186 and IL-1β are expected to be potential diagnostic biomarkers for non-small cell lung cancer.
Keywords: miR-186, interleukin-1β, non-small cell lung cancer, diagnosis, exhaled breath condensate
Introduction
According to global cancer statistics in 2018, Lung cancer is ranked as the most common tumor in males and females and the leading cause of cancer death (18.4% of total cancer deaths) worldwide.1 Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, accounting for nearly 80% of lung cancer. Despite advances in NSCLC prognosis with new pharmaceutical products and technological improvements, finding convenient and effective biomarkers remains a significant challenge.2,3 Fortunately, an increasing number of new biomarkers have been discovered in traditional matrices, such as serum, and new non-invasively collected body fluids. Exhaled breath condensate (EBC) is obtained by introducing exhaled breath into a cryogenic system and condensing into a liquid. Various proteins, cell debris, DNA, microRNAs, and microbiota (bacteria and viruses) are successively detected in EBC.4 Studies have shown that miRNA expression is deregulated in EBC from patients with NSCLC.
MicroRNAs, a class of 18-25 nt noncoding small RNAs, play a key role in regulating cancer development through various biological processes (angiogenesis, cell proliferation, migration, invasion, differentiation, and apoptosis).5-7 Among tumor-associated miRNAs, miR-186 located in the chromosome band 1q31.1 has attracted considerable attention. miR-186 serves a dual function in a variety of cancers. A reduction in miR-186 was investigated in stomach cancer, NSCLC, liver cancer, oral squamous cell carcinoma, pancreatic cancer and breast cancer. However, it plays the opposite role in endometrial cancer, lymphoma, and peritoneal cancer.8-13 miR-186 plays an essential role in the genetics of human NSCLC. A downregulation in miR-186 was found in NSCLC tissues and cells. By targeting different genes, miR-186 can inhibit the cell cycle progression, proliferation, migration, and invasion of NSCLC.14-20 However, no study has established the expression of NSCLC miR-186 in serum and EBC. Moreover, the mechanism of miR-186 in NSCLC is not fully understood.
Chronic inflammation is a key factor in tumorigenesis, and the critical role of inflammation in cancer is well accepted worldwide today.21,22 Recently, increasing evidence shows that miRNAs are a new class of inflammation-related molecules involved in multiple stages of tumor development, such as initiation, tumor progression, invasion, and metastasis. Tumor-associated miRNAs can regulate a range of inflammatory factors. Studies have shown that miRNA186 can inhibit Interleukin-1β (IL-1β) expression by regulating NLRP3 inflammasome, suggesting that miRNA186 may participate in tumorigenesis by regulating the tumor microenvironment.23 IL-1β plays a pro-inflammatory cytokine role involved in inflammatory responses, both acute and chronic. Multiple experiments in vitro and vivo have shown that IL-1β has a tumor-promoting effect and can promote lung cancer metastasis through adhesion, invasion, and tumor angiogenesis of lung cancer cells.24
In the present experiment, we examined the levels of miR-186 and IL-1β in serum and EBC and explored the clinical significance of miR-186 and IL-1β levels in NSCLC. The correlation between serum miR-186 and IL-1β was performed.
Materials and Methods
Patients
A total of 62 NSCLC patients who were treated in the Department of Thoracic Surgery and Respiratory Medicine of Affiliated Hospital 2 of Nantong University between September 2017 and September 2019 were enrolled in our study. All patients were eligible according to the following inclusion criteria: (a) NSCLC was diagnosed by pathological examination; (b) the subjects did not undergo chemotherapy, immunotherapy, or surgery before collection; and (c) patients had no lung inflammatory diseases. At the same time, a total of 60 healthy individuals were selected as the control group, and the control group had no history of malignant tumors and no systemic organ diseases. Tumor staging was assessed using the TNM staging of lung cancer published by the 2017 International Union Against Cancer. The clinical characteristics of the study participants are expressed in Table 1. The collection of all samples was approved by the Medical Ethics Committee of the Affiliated Hospital 2 of Nantong University (approval no. 2019KY139), and patients’ written informed consent was obtained.
Table 1.
Characteristics of the Study Participants.
| NSCLC (n = 62) | Control (n = 60) | P value | |
|---|---|---|---|
| Age (years) | 62.05 ± 9.24 | 59.48 ± 7.56 | >0.05 |
| Gender | |||
| Male | 32 | 29 | >0.05 |
| Female | 30 | 31 | |
| Smoking | |||
| Yes | 27 | 35 | >0.05 |
| No | 35 | 25 | |
| BMI | |||
| <25 | 48 | 45 | >0.05 |
| ≥25 | 14 | 15 | |
| Histological type | |||
| Adenocarcinoma | 45 | - | |
| Squamous cell carcinoma | 17 | - | |
| Lymph node metastasis | |||
| Yes | 28 | - | |
| No | 34 | - | |
| TNM stage | |||
| I-II | 33 | - | |
| III-IV | 29 | - |
Abbreviations: BMI: body mass index.
p-values were determined using Student’s t-test, or the chi-square test as appropriate.
Specimen Collection
The blood and EBC specimens of the study participants were collected on the first day of admission. Serum specimen: 3 ml of fasting blood was collected and placed in a coagulation tube. The supernatant was collected after centrifugation at 3500 rpm for 5 min. EBC specimens: EBC specimens were collected using an EcoScreen condenser manufactured by Eric Jaeger Company. The subjects were asked to breathe into the collecting system for 15 min at −20°C.25 All specimens were stored in a −70°C low-temperature refrigerator for the following inspection.
RNA Extraction and Real-Time Fluorescent Quantitative PCR (qRT-PCR)
Total RNA was extracted from serum and EBC using the miRNA extraction kit (Tiangen DP503, China) in accordance with the manufacturer’s protocol. Then, total RNA containing miRNA was reverse transcribed to cDNA by using the miRNA cDNA first strand synthesis kit (Tiangen KR211, China). The qRT-PCR was performed on a StepOnePlus real-time PCR instrument by using the SYBR Green I fluorescent dye method. miR-39 was selected as the external reference gene because of its stable presence in the serum according to previous studies.26 Three replicate wells were provided for each sample. The relative expression of miR-186 was calculated by using the 2-ΔΔCt method, where ΔΔCt = NSCLC (Ct target gene − Ct reference gene) − healthy controls (Ct target gene − Ct reference gene).
Enzyme-Linked Immunosorbent Assay (ELISA)
IL-1β concentration was determined using the Proteintech ELISA kit (catalog number: KE00021, USA), and the procedure was carried out in strict accordance with the kit’s instructions.
Statistical Analysis
Statistical analysis was performed by IBM SPSS Statistics, and graphs were generated using GraphPad Prism 7.0. The data distribution of each group was assessed by the Kolmogorov−Smirnov test. For the normal distribution data, 2 group comparisons were conducted using Student’s t-test when the variance is equal. When the variance is not uniform, t-test (Satterthwaite method) was used, and continuous variables were summarized as the mean ± standard deviation. Non-normally distributed data were analyzed using the Mann–Whitney U, and Continuous variables were presented as median (interquartile range). The chi-square (χ2) test was used to compare the distribution of categorical variables between groups. Pearson correlation was used to determine the association between variables. The diagnostic value of miR-186 and IL-1β to differentiate NSCLC patients and controls was assessed using receiver operating characteristic (ROC) curve analysis. P < 0.05 was considered statistically significant.
Results
Decreased Expression of Serum and EBC miRNA186 in NSCLC
To explore the clinical value of miR-186 in NSCLC, we first measured the relative expression of miR-186 in serum and EBC of 62 patients with NSCLC and 60 age- and sex-matched healthy controls by qRT-PCR. As shown in Figure 1, the relative expression of miR-186 was significantly decreased in patients with NSCLC than in controls in serum and EBC (P < 0.05). In addition, a low expression of miR-186 was observed in patients with stage I−II NSCLC when compared with the stage III−IV group (P < 0.05). The difference in miR-186 expression between patients with I−II NSCLC and healthy controls was significant (P < 0.05).
Figure 1.
The relative expression of serum (A and B) and EBC (C and D) miR-186 in controls and NSCLC patients. *P < 0.05; **P < 0.01; ***P < 0.001; ****P ≤ 0.0001.
Correlation Analysis of miR-186 in Serum and EBC
Then, the correlation between the expression levels of miR-186 in serum and EBC was analyzed by Pearson correlation. in Figure 2, the level of miR-186 in serum is positively related to that in EBC (r = 0.480, P < 0.05).
Figure 2.
Correlation scatter diagram of miR-186 level in EBC and serum.
Increased IL-1β Concentration in Serum and EBC of NSCLC
IL-1β concentrations in the serum and EBC of patients with NSCLC and healthy controls were detected using ELISA. The serum IL-1β level in patients with NSCLC was significantly higher than that in healthy controls. Statistics showed a progressive upregulation of IL-1β with increasing NSCLC severity, represented by TNM staging(P < 0.05, Figures 3A and B). Similarly, Figure 3C and D showed higher concentration of IL-1β in EBC from NSCLC patients when compared with healthy controls. IL-1β concentration was related to TNM staging (P < 0.05).
Figure 3.
Concentrations of IL-1β in serum (A and B) and EBC (C and D) in controls and NSCLC patients.
Association Between miRNA186 and IL-1β and Clinical Features in Patients With NSCLC
The correlation between the expression level of miR-186 and IL-1β and clinicopathological characteristics of NSCLC was investigated (Tables 2 and 3). The serum levels of miR-186 in the lymph node metastasis group were significantly lower than those in the non-metastasis group, and higher concentration of IL-1β was observed in lymph node metastasis group (P < 0.05, Table 2). The serum levels of miR-186 and IL-1β were not significantly associated with age, sex, and smoking history (P > 0.05, Table 2). The squamous cell carcinoma group had a higher serum IL-1β level compared with the adenocarcinoma group (P < 0.05, Table 2). However, there was no significant association between serum miR-186 level and histological type of NSCLC (P > 0.05, Table 2).
Table 2.
Correlation Between miRNA186, IL-1β Level in Serum and Clinical Characteristics in NSCLC.
| Characteristics | N | Serum | |
|---|---|---|---|
| miR-186 | IL-1β (pg/ml) | ||
| Age(years) | |||
| ≤ 60 | 25 | 0.637 ± 0.209 | 131.400 ± 27.720 |
| >60 | 37 | 0.661 ± 0.332 | 138.700 ± 31.140 |
| P value | 0.727 | 0.348 | |
| Gender | |||
| Male | 32 | 0.702 ± 0.311 | 134.100 ± 27.410 |
| Female | 30 | 0.598 ± 0.253 | 137.400 ± 35.530 |
| P value | 0.159 | 0.671 | |
| Smoking | |||
| Yes | 27 | 0.500 (0.380-0.780) | 129.600 ± 27.990 |
| No | 35 | 0.670 (0.460-0.820) | 143.600 ± 30.720 |
| P value | 0.214 | 0.067 | |
| Histological type | |||
| Adenocarcinoma | 45 | 0.653 ± 0.283 | 130.700 ± 28.250 |
| Squamous cell carcinoma | 17 | 0.647 ± 0.306 | 148.900 ± 30.550 |
| P value | 0.940 | 0.031 | |
| Lymph node metastasis | |||
| Yes | 28 | 0.495 (0.393-0.693) | 149.600 ± 30.760 |
| No | 34 | 0.710 (0.515-0.863) | 124.200 ± 23.790 |
| P value | 0.013 | 0.001 | |
Table 3.
Correlation Between miRNA186, IL-1β Level in EBC and Clinical Characteristics in NSCLC.
| Characteristics | N | EBC | |
|---|---|---|---|
| miR-186 | IL-1β (pg/ml) | ||
| Age(years) | |||
| ≤ 60 | 25 | 0.464 ± 0.210 | 20.660 (19.820-25.880) |
| >60 | 37 | 0.524 ± 0.285 | 21.070 (19.820-26.200) |
| P value | 0.368 | 0.929 | |
| Gender | |||
| Male | 32 | 0.459 ± 0.213 | 21.600 (20.080-25.880) |
| Female | 30 | 0.538 ± 0.291 | 20.660 (19.350-25.930) |
| P value | 0.235 | 0.188 | |
| Smoking | |||
| Yes | 27 | 0.546 ± 0.313 | 21.070 (20.030-26.510) |
| No | 35 | 0.464 ± 0.201 | 20.660 (19.610-23.370) |
| P value | 0.243 | 0.158 | |
| Histological type | |||
| Adenocarcinoma | 45 | 0.459 ± 0.242 | 21.070 (19.510-25.880) |
| Squamous cell carcinoma | 17 | 0.607 ± 0.272 | 21.070 (20.240-26.410) |
| P value | 0.042 | 0.524 | |
| Lymph node metastasis | |||
| Yes | 28 | 0.538 ± 0.265 | 21.600 (20.240-26.350) |
| No | 34 | 0.468 ± 0.250 | 20.870 (19.400-25.410) |
| P value | 0.288 | 0.340 | |
Table 3 shows that the expression level of miR-186 in EBC was lower in adenocarcinoma than in squamous cell carcinoma (P < 0.05). The correlation between miR-186 and IL-1β expression level in EBC and other clinicopathological factors, including age, sex, smoking history, and lymph node metastasis, was found to be non-significant (P > 0.05).
Correlation Between Serum miRNA186 and IL-1β Level and Traditional Tumor Markers and Inflammatory Markers
The correlation between serum levels of miR-186, IL-1β and traditional tumor markers in NSCLC patients was explored. The expression of serum miR-186 was significantly lower in NSCLC with higher carcinoembryonic antigen (CEA) level (P < 0.05, Table 4), and no statistically significant associations were found between miR-186 expression and other abovementioned tumor markers, such as cytokeratin-19-fragment, squamous cell carcinoma associated antigen, and neuron-specific enolase (P > 0.05, Table 4). The correlation between IL-1β levels and traditional tumor markers were found to be non-significant(P > 0.05, Table 4).
Table 4.
Correlation Between Serum miRNA186, IL-1β Level and Traditional Tumor Biomarker, Inflammatory Factor.
| Factors | N | miRNA186 | IL-1β (pg/ml) |
|---|---|---|---|
| CEA (ng/ml) | |||
| ≤2.90 | 32 | 0.72 ± 0.30 | 128.70 ± 30.86 |
| >2.90 | 30 | 0.58 ± 0.25 | 143.20 ± 27.14 |
| P value | 0.048 | 0.055 | |
| CA211 (ng/ml) | |||
| ≤3.27 | 31 | 0.67 (0.49-0.86) | 129.90 ± 28.27 |
| >3.27 | 31 | 0.50 (0.40-0.78) | 141.50 ± 30.60 |
| P value | 0.205 | 0.128 | |
| SCC (ng/ml) | |||
| ≤0.77 | 35 | 0.62 (0.40-0.80) | 131.30 ± 26.34 |
| >0.77 | 27 | 0.62 (0.48-0.82) | 141.40 ± 33.41 |
| P value | 0.670 | 0.191 | |
| NSE (ng/ml) | |||
| ≤16.38 | 32 | 0.71 ± 0.33 | 131.60 ± 34.48 |
| >16.38 | 30 | 0.59 ± 0.22 | 140.10 ± 23.61 |
| P value | 0.102 | 0.260 | |
| PCT (ng/ml) | |||
| ≤0.034 | 32 | 0.66 ± 0.31 | 132.20 ± 28.54 |
| >0.034 | 30 | 0.64 ± 0.26 | 139.40 ± 31.12 |
| P value | 0.781 | 0.346 | |
| ESR (mm/h) | |||
| ≤10 | 34 | 0.72 ± 0.30 | 126.60 ± 26.39 |
| >10 | 28 | 0.57 ± 0.25 | 146.80 ± 30.37 |
| P value | 0.031 | 0.007 | |
| CRP (mg/L) | |||
| ≤5.395 | 31 | 0.80 ± 0.35 | 126.70 ± 26.44 |
| >5.395 | 31 | 0.57 ± 0.28 | 144.70 ± 30.65 |
| P value | 0.001 | 0.017 |
CEA: carcinoembryonic antigen; CA21: Cytokeratin-19-fragment; SCC: sguamous cell carcinoma associated antigen; NSE: neuron-specific enolase; PCT: procalcitonin; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
Recently, increasing evidence exhibites that miRNAs are a new class of inflammation-related molecules. Thus, we analyzed the association between the serum level of miR-186, IL-1β and procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with NSCLC. The results are shown in Table 4. The low expression level of serum miR-186 and the high concentration of IL-1β were associated with high serum CRP and ESR levels (P < 0.05). The correlation between miR-186 and IL-1β level and PCT were found to be non-significant (P > 0.05).
Diagnosis Efficacy of miR-186 and IL-1β Expression in NSCLC
The ROC curve was drawn in accordance with the expression levels of miR-186 and IL-1β in serum and EBC of NSCLC patients and healthy controls. The Youden index (sensitivity + specificity − 1) was used to determine the Cutoff value. ROC curve analysis revealed that serum miR-186 could distinguish NSCLC patients from controls with area under the curve (AUC) value of 0.801, and the sensitivity and specificity were 80.6% and 73.3%, respectively. Similarly, serum IL-1β could serve as a reliable biomarker for differentiating NSCLC patients from controls with 80.0% specificity, 83.9% sensitivity, and an AUC value of 0.829. Interestingly, the AUC of combined detection was 0.850, which was significantly better than that of miR-186 and IL-1β, and the sensitivity and specificity were 72.6% and 91.7%, respectively (Figure 4, Table 5).
Figure 4.
Receiver operating curve (ROC) curve analysis with the use of serum miRNA186, IL-1β to differentiate NSCLC patients and healthy controls.
Table 5.
Diagnosis Performance of Serum miRNA186, IL-1β.
| Index | AUC | P value | 95%CI | Sensitivity (%) | Specificity (%) | Cutoff value |
|---|---|---|---|---|---|---|
| miRNA186 | 0.801 | <0.001 | 0.722-0.881 | 80.6 | 73.3 | 0.513 |
| IL-1β | 0.829 | <0.001 | 0.752-0.906 | 83.9 | 80.0 | 109.715 |
| miRNA186+IL-1β | 0.850 | <0.001 | 0.780-0.920 | 72.6 | 91.7 | 0.551 |
ROC curve analysis was used to evaluate the capability of serum and EBC miR-186 to discriminate between NSCLC patients and controls. The highest AUC was indicated for EBC miR-186. The AUC of the combined detection of miR-186 in serum and EBC was 0.863 with sensitivity and specificity of 75.8% and 83.3%, respectively (Figure 5, Table 6).
Figure 5.
Receiver operating curve (ROC) curve analysis with the use of serum and EBC miR-186 to differentiate NSCLC patients and healthy controls samples.
Table 6.
Diagnosis Performance of Serum and EBC miRNA186.
| Index | AUC | P value | 95%CI | Sensitivity (%) | Specificity (%) | Cutoff value |
|---|---|---|---|---|---|---|
| Serum | 0.801 | <0.001 | 0.722-0.881 | 80.6 | 73.3 | 0.513 |
| EBC | 0.826 | <0.001 | 0.752-0.900 | 75.8 | 78.3 | 0.601 |
| Serum +EBC | 0.863 | <0.001 | 0.797-0.928 | 75.8 | 83.3 | 0.618 |
Correlation Between miR-186 and IL-1β in Serum
We evaluated the relationship between miR-186 and IL-1β in serum and found a negative correlation between IL-1β and miR-186 (r = −0.640, P < 0.05, Figure 6).
Figure 6.
Correlation scatter diagram of miR-186 and IL-1β levels in serum.
Discussion
In our study, serum and EBC miR-186 expression levels can discriminate NSCLC patients from healthy controls. Moreover, miR-186 expression among patients with stage III-IV NSCLC was remarkably lower than that of patients with stage I-II NSCLC. These results agreed with numerous studies that reported reduced miR-186 expression in NSCLC tissues and cells. It meaned that miR-186 plays a tumor suppressor gene role in NSCLC and is associated with the extent of disease progression. Our work reported for the first time that miR-186 is down-expressed in serum and EBC samples collected from NSCLC patients.
By binding the 3’-untranslated region (3’-UTR) of cyclin-dependent kinase 1 (CDK1), miR-186 reduces CDK1 expression in NSCLC cells, at the same time, it inhibits lung cancer cells growth.27 Cell division cycle 42 (cdc42) serves a key function in regulating migration, and miR-186 can directly target cdc42, whitch is proved to modulate epithelial-mesenchymal transition by adjusting E-cadherin, vimentin, and a-SMA.15 Cyclin D1, CDK2, and CDK6, serve as cell cycle promoters, can directly target miR-186. A negative correlation between miR-186 expression level and the above-mentioned cell cycle promoter levels has been found by Junchao and colleagues.28 Furthermore, miR-186 regulates the chemo-sensitivity in NSCLC cells by directly targeting microtubule associated protein tau (MAPT).19
The pathogenesis of lung cancer is complex, and immune inflammatory reactions are involved. In addition to participating in the body’s inflammatory response and its own anti-infective defense, IL-1β participates in the occurrence and metastasis of some malignant tumors. IL-1β is involved in NSCLC progression and may be involved in immunosuppression and in promoting NSCLC development.29 A study proposed the possibility that anti-inflammatory therapy by targeting IL-1β may reduce the prevalence of lung cancer among patients who have higher CRP.30 Recently, a phase 3 clinical trial has reported an interesting result, anakinumab, an inhibitory antibody targeting IL-1β, could significantly reduce the incidence and mortality of lung cancer.31
Similar to previous studies, our experiments indicated that IL-1β concentration in serum and EBC from patients with NSCLC is enhanced compared with that of healthy controls, and IL-1β level is related to disease stage. Meanwhile, serum IL-1β concentration is negatively correlated with miR-186, both of them were associated with NSCLC.
This study indicates that the expression of miR-186 level in serum is negatively associated with lymph node metastasis. We did not find any correlation between the expression level of serum miR-186 and age, sex, smoking history, and histological type. Yet, EBC miR-186 level was correlated with histological type but not lymph node metastasis. The reasons for these results may be as follows: first, the sample size of our experiment was very small; second, miR-186 and pathological types might not be related;finally, EBC samples were obtained from a location close to the lesion.
Few studies have compared miRNAs with traditional tumor markers. We studied the relationship between serum miR-186 level and traditional tumor biomarkers and inflammatory factors. Interestingly, we found that serum miR-186 expression was associated with CEA, ESR, and CRP.
The ROC curve was performed to estimate the diagnostic efficacy of miR-186, and the AUC of EBC miR-186 was higher than that in the serum. EBC miR-186 has better NSCLC diagnostic efficacy and higher specificity, indicating that EBC miR-186 is more effective than serum in NSCLC diagnosis. The sensitivity of the combined detection was 75.8%, the specificity was 83.3%, and the AUC of combined detection was significantly better than that in separate detection.
This work still has some shortcomings. First, the sample size is small and needs to be further expanded. Second, experimental results suggest the link between miR-186 and IL-1β, which may be related to the development of NSCLC. This finding provides new perspective for the promotion of tumorigenesis by inflammation. However, the specific mechanism of miR-186 and IL-1β on NSCLC remains unclear, and relevant experiments are needed.
In summary, the expression levels of miR-186 and IL-1β in serum and EBC contribute to the diagnosis and severity assessment of NSCLC. Thus, miR-186 and IL-1β are expected to be potential diagnostic markers for NSCLC.
Abbreviations
- CEA
carcinoembryonic antigen
- CRP
C-reactive protein
- EBC
exhaled breath condensate
- ELISA
enzyme linked immunosorbent assay
- ESR
erythrocyte sedimentation rate
- IL-1β
interleukin-1β
- NSCLC
non-small cell lung cancer
- PCT
procalcitonin
- qRT-PCR
real-time fluorescent quantitative PCR
- ROC
receiver operating characteristic
Footnotes
Authors’ Note: Haiqin Xie and Jinliang Chen contributed equally and are joint first authors.
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a grant from the Scientific Research Project of Health Commission of Jiangsu Province (NO. H2018035); the Scientific Research Project of “333 Project” in Jiangsu Province (NO. BRA2018224); Science and Technology Project of Nantong (NO. HS2018002 and JC2019031); Science and Technology Project of Jiangsu (NO. BK20191207).
ORCID iD: Haiqin Xie, MSc 
https://orcid.org/0000-0002-9109-1299
References
- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. [DOI] [PubMed] [Google Scholar]
- 2. Yang B, Li X, Ren T, Yin Y. Autoantibodies as diagnostic biomarkers for lung cancer: a systematic review. Cell Death Discov. 2019;5:126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Roointan A, Ahmad Mir T, Ibrahim Wani S, et al. Early detection of lung cancer biomarkers through biosensor technology: a review. J Pharm Biomed Anal. 2019;164:93–103. [DOI] [PubMed] [Google Scholar]
- 4. Winters BR, Pleil JD, Angrish MM, Stiegel MA, Risby TH, Madden MC. Standardization of the collection of exhaled breath condensate and exhaled breath aerosol using a feedback regulated sampling device. J Breath Res. 2017;11(4):047107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Cui M, Wang H, Yao X, et al. Circulating MicroRNAs in cancer: potential and challenge. Front Genet. 2019;10:626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers (Basel). 2019;11(8):1170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Wu KL, Tsai YM, Lien CT, Kuo PL, Hung JY. The roles of microRNA in lung cancer. Int J Mol Sci. 2019;20(7):1611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Niu Q, Li X, Xia D, et al. MicroRNA-186 affects the proliferation of tumor cells via yes-associated protein 1 in the occurrence and development of pancreatic cancer. Exp Ther Med. 2017;14(3):2094–2100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. He W, Feng J, Zhang Y, Wang Y, Zang W, Zhao G. microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2. Lab Invest. 2016;96(3):317–324. [DOI] [PubMed] [Google Scholar]
- 10. He X, Ping J. MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C. Exp Ther Med. 2017;14(4):3253–3258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Wang H, Ou J, Jian Z, Ou Y. miR-186 modulates hepatocellular carcinoma cell proliferation and mobility via targeting MCRS1-mediated Wnt/β-catenin signaling. J Cell Physiol. 2019;234(12):23135–23145. [DOI] [PubMed] [Google Scholar]
- 12. Zare A, Alipoor B, Omrani MD, Zali MR, Alamdari NM, Ghaedi H. Decreased miR-155-5p, miR-15a, and miR-186 expression in gastric cancer is associated with advanced tumor grade and metastasis. Iran Biomed J. 2019;23(5):338–343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Sun WJ, Zhang YN, Xue P. miR-186 inhibits proliferation, migration, and epithelial-mesenchymal transition in breast cancer cells by targeting Twist1. J Cell Biochem. 2019;120(6):10001–10009. [DOI] [PubMed] [Google Scholar]
- 14. Huang T, Wang G, Yang L, et al. MiR-186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1. Cancer Biomark. 2017;21(1):221–228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Dong Y, Jin X, Sun Z, Zhao Y, Song X. MiR-186 inhibited migration of NSCLC via targeting cdc42 and effecting EMT process. Mol Cells. 2017;40(3):195–201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Huang T, She K, Peng G, et al. MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer. Int J Oncol. 2016;49(4):1437–1444. [DOI] [PubMed] [Google Scholar]
- 17. Ruan L, Chen J, Ruan L, Yang T, Wang P. MicroRNA-186 suppresses lung cancer progression by targeting SIRT6. Cancer Biomark. 2018;21(2):415–423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Cui G, Cui M, Li Y, et al. MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells. Tumour Biol. 2014;35(9):8933–8937. [DOI] [PubMed] [Google Scholar]
- 19. Ye J, Zhang Z, Sun L, Fang Y, Xu X, Zhou G. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst. 2016;12(11):3417–3424. [DOI] [PubMed] [Google Scholar]
- 20. Li H, Yin C, Zhang B, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013;34(9):2145–2155. [DOI] [PubMed] [Google Scholar]
- 21. Zhong Z, Sanchez-Lopez E, Karin M. Autophagy, inflammation, and immunity: a troika governing cancer and its treatment. Cell. 2016;166(2):288–298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Coffelt SB, de Visser KE. Cancer: inflammation lights the way to metastasis. Nature. 2014;506(7490):48–50. [DOI] [PubMed] [Google Scholar]
- 23. Chen ML, Lin K, Lin SK. NLRP3 inflammasome signaling as an early molecular response is negatively controlled by miR-186 in CFA-induced prosopalgia mice. Braz J Med Biol Res. 2018;51(9):e7602. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Wu C, Li X, Zhang D, et al. IL-1β-mediated up-regulation of WT1D via miR-144-3p and their synergistic effect with NF-κB/COX-2/HIF-1α pathway on cell proliferation in LUAD. Cell Physiol Biochem. 2018;48(6):2493–2502. [DOI] [PubMed] [Google Scholar]
- 25. Chen J, Chen J, Lv X, Yang Q, Yao S. Epidermal growth factor in exhaled breath condensate as diagnostic method for non-small cell lung cancer. Technol Cancer Res Treat. 2019;18:1533033819872271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Zaleski M, Kobilay M, Schroeder L, et al. Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget. 2018;9(32):22523–22536. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Li L, Zhang Z, Yang Q, Ning M. Lycorine inhibited the cell growth of non-small cell lung cancer by modulating the miR-186/CDK1 axis. Life Sci. 2019;231:116528. [DOI] [PubMed] [Google Scholar]
- 28. Cai J, Wu J, Zhang H, et al. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res. 2013;73(2):756–766. [DOI] [PubMed] [Google Scholar]
- 29. Lasithiotaki I, Tsitoura E, Samara KD, et al. NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. PLoS One. 2018;13(10):e0205242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–1842. [DOI] [PubMed] [Google Scholar]
- 31. Wu TC, Xu K, Martinek J, et al. IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer. Cancer Res. 2018;78(18):5243–5258. [DOI] [PMC free article] [PubMed] [Google Scholar]